Pediatric scalp psoriasis: Therapeutic response to oral apremilast: A report of two cases

Abstract

Localized childhood scalp psoriasis is usually controlled with topical therapy. Therapies resistant to topical treatment require a switch to oral therapy. Standardized guidelines for treating childhood psoriasis are lacking, and there are only limited evidence-based data and approved treatments. However, in this current pandemic situation, oral immunosuppressants should be avoided, and a safer molecule-like apremilast can be a better option. We present two cases of childhood scalp psoriasis not responding to topical therapy and showing excellent results with apremilast with better safety profile.

Keywords

• apremilast in pediatric age group
• apremilast in scalp psoriasis
• pediatric scalp psoriasis